GNI Group Ltd
TSE:2160

Watchlist Manager
GNI Group Ltd Logo
GNI Group Ltd
TSE:2160
Watchlist
Price: 3 380 JPY 5.13% Market Closed
Market Cap: 169.4B JPY
Have any thoughts about
GNI Group Ltd?
Write Note
GNI Group Ltd
/
Income Statement
/
Gain/Loss on Disposition of Assets

GNI Group Ltd
Gain/Loss on Disposition of Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GNI Group Ltd
Gain/Loss on Disposition of Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gain/Loss on Disposition of Assets CAGR 3Y CAGR 5Y CAGR 10Y
GNI Group Ltd
TSE:2160
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Gain/Loss on Disposition of Assets
-¥345m
CAGR 3-Years
-58%
CAGR 5-Years
N/A
CAGR 10-Years
-23%
Pharma Foods International Co Ltd
TSE:2929
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
StemRIM Inc
TSE:4599
Gain/Loss on Disposition of Assets
¥313k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GNI Group Ltd
Glance View

Market Cap
169.2B JPY
Industry
Biotechnology

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Intrinsic Value
4 956.28 JPY
Undervaluation 32%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.